Pittsburgh Life Sciences Greenhouse

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company specializes in developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. By enabling pre-hospital providers to accurately assess patients, AlphaStroke facilitates timely triage and enhances decision-making in critical care scenarios, ultimately aiming to reduce treatment delays and improve patient outcomes.

Neuro Kinetics, Inc. is a medical technology company based in Pittsburgh, Pennsylvania, specializing in eye tracking technology and non-invasive neuro-otologic diagnostic testing tools. Founded in 1984, the company serves a global clientele of audiologists, ENT specialists, neuro-otologists, neuro-ophthalmologists, and neurologists. Its product portfolio includes the I-PORTAL Neuro-Otologic Test Center, which provides a comprehensive vestibular testing solution, along with various software and diagnostic tools such as VEST for neuro-otologic analysis, Video Nystagmography, and Video Oculography for vestibular assessments. Neuro Kinetics also offers training, maintenance, and support services to enhance the use of its products. By providing tools for the evaluation of neurologic, otologic, and vestibular disorders, Neuro Kinetics enables healthcare professionals to initiate treatment more promptly, thereby improving the chances of successful outcomes for patients.

Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.

Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Ariel Precision Medicine, Inc. is an integrated genomics and digital health company focused on providing precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases and disorders. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, the company develops innovative clinical decision support tools aimed at simplifying personalized treatment in both emergency departments and clinical settings. One of its key offerings is ArielDx, a cloud-based tool designed to enhance the diagnosis and treatment of pancreatic disease, thereby improving patient outcomes through tailored healthcare solutions.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company specializes in developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. By enabling pre-hospital providers to accurately assess patients, AlphaStroke facilitates timely triage and enhances decision-making in critical care scenarios, ultimately aiming to reduce treatment delays and improve patient outcomes.

Better Body Image, Inc. is a company based in Pittsburgh, Pennsylvania, that focuses on health and fitness through its innovative mobile application. Founded in 2013, Better Body Image develops personalized exercise routines tailored to individual body types, activity levels, and fitness goals. The company's flagship app, Better Body Image, employs proprietary data and advanced visualization technology to illustrate potential transformations in users' bodies as they work toward their desired weight and wellness objectives. This app serves as a motivational tool, helping users track their progress and manage their health. Additionally, Better Body Image has introduced a new application, "View2Lose," which features patented artificial intelligence to enhance user engagement. Through strategic partnerships, including a collaboration with AI Ventures, the company aims to expand its reach and achieve significant download milestones, while also securing funding to support its growth initiatives.

Medrobotics Corporation, founded in 2005 and based in Raynham, Massachusetts, specializes in the development and commercialization of robotic surgical products. The company's flagship product is the Flex Robotic System, a robot-assisted platform designed to provide surgeons with single-site access and visualization of hard-to-reach anatomical locations. This system features a steerable and shapeable robotic scope, allowing surgeons to navigate complex anatomy through a small entry point. Medrobotics also offers a range of instruments compatible with the Flex system, including retractors and various surgical tools. The company's products are marketed in Europe.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics. Founded in 2008, the company employs a tissue systems biology approach to anatomic pathology, focusing on comprehensive evaluations of tumors composed of various cell types. Cernostics has developed the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess risk in Barrett’s esophagus patients, thereby aiding gastroenterologists in treatment decisions. The company’s innovative platform features advanced capabilities such as multi-channel fluorescence imaging, image reading, image segmentation, and biomarker expression analysis. Cernostics aims to provide insights into disease pathophysiology, facilitate biomarker discovery and validation, and support clinical trials, ultimately enhancing patient outcomes and reducing healthcare costs. The company also collaborates strategically with Deciphex Limited to further advance its technological initiatives.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

ALung Technologies, Inc., established in 1997 and based in Pittsburgh, Pennsylvania, specializes in developing and manufacturing medical devices for treating acute respiratory failure. The company's primary product is the Hemolung Respiratory Assist System, a dialysis-like device that removes carbon dioxide and delivers oxygen directly to the blood, allowing patients' lungs to rest and heal while avoiding intubation and facilitating protective ventilation.

ATRP SOLUTIONS develops and manufactures specialty polymers that meet their needs. It recognizes the polymeric materials for improving the performance of commercial products in the areas of personal care and cosmetics, detergents and surfactants, paints, pigments, coatings, and biocompatible materials. It was founded in 2006 and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

ClearCount Medical Solutions is a developer of patient safety solutions specifically designed for operating rooms. The company offers a unique sponge management system that integrates counting and detection capabilities, utilizing an RFID-based platform to enhance surgical accuracy. This innovative system allows for quick reconciliation of sponge counts and features the SmartWand, which aids in locating any missing sponges in the event of a count discrepancy. By providing a comprehensive solution for sponge reconciliation and detection, ClearCount aims to improve patient safety and operational efficiency in surgical settings.

QuantumOPS is an orthopedic technology company focused on enhancing surgical outcomes through innovative equipment designed for modern operating rooms. The company develops a range of orthopedic products, including a shoulder positioning system and a carbon operative arm positioner, along with various accessories that support head and body positioning. These products facilitate the immobilization and stabilization of patients of all sizes during shoulder surgeries, thereby improving the efficiency and effectiveness of surgical procedures. QuantumOPS emphasizes user involvement throughout the design process, ensuring that the needs of clinicians, orthopedic surgeons, nurses, and anesthesiologists are met. The company is recognized for its agility and responsiveness to market demands, positioning itself as a valuable partner in the field of orthopedic technology.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Medrobotics Corporation, founded in 2005 and based in Raynham, Massachusetts, specializes in the development and commercialization of robotic surgical products. The company's flagship product is the Flex Robotic System, a robot-assisted platform designed to provide surgeons with single-site access and visualization of hard-to-reach anatomical locations. This system features a steerable and shapeable robotic scope, allowing surgeons to navigate complex anatomy through a small entry point. Medrobotics also offers a range of instruments compatible with the Flex system, including retractors and various surgical tools. The company's products are marketed in Europe.

QuantumOPS is an orthopedic technology company focused on enhancing surgical outcomes through innovative equipment designed for modern operating rooms. The company develops a range of orthopedic products, including a shoulder positioning system and a carbon operative arm positioner, along with various accessories that support head and body positioning. These products facilitate the immobilization and stabilization of patients of all sizes during shoulder surgeries, thereby improving the efficiency and effectiveness of surgical procedures. QuantumOPS emphasizes user involvement throughout the design process, ensuring that the needs of clinicians, orthopedic surgeons, nurses, and anesthesiologists are met. The company is recognized for its agility and responsiveness to market demands, positioning itself as a valuable partner in the field of orthopedic technology.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Rinovum Women's Health, Inc. develops medical devices for women. It offers Stork, a medical device that aids in natural fertility and conception in the privacy of home.

STARR Life Sciences Corp. specializes in developing and manufacturing equipment for small animal research, catering to the needs of life science laboratories globally. Founded in 2004 and based in Oakmont, Pennsylvania, the company offers a diverse range of products designed specifically for mice, rats, and other small animals. Key offerings include the MouseOX Plus, a pulse oximeter that measures vital signs such as heart rate and arterial oxygen saturation, and the E-Mitter Telemetry System, which allows continuous monitoring of temperature, motor activity, and heart rate. Additionally, STARR Life Sciences provides various sensors, software modules, and activity monitoring systems that enable researchers and veterinarians to track the health and behavior of their subjects without causing disruption. Their products are utilized by universities, pharmaceutical companies, and contract research organizations, reflecting the company’s commitment to advancing medical research through innovative solutions.

Applied Computational Technologies is a software development company specializing in applications for the life sciences sector, particularly in radiation treatment planning for cancer therapy. The company has developed innovative software products, including ProACTive, a dose calculation engine designed to facilitate treatment planning for adaptive radiotherapy. With a significant number of cancer diagnoses in the United States, where a large percentage of patients undergo radiation therapy, Applied Computational Technologies aims to enhance the precision and effectiveness of cancer treatments through its advanced technological solutions.

NeuroInterventional Therapeutics, Inc. ("NIT", dba Neurointerventions, Inc.) is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus ("blood clots") in a wide range of cerebral vessels, thereby increasing chances of survival and minimizing disability.

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics. Founded in 2008, the company employs a tissue systems biology approach to anatomic pathology, focusing on comprehensive evaluations of tumors composed of various cell types. Cernostics has developed the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess risk in Barrett’s esophagus patients, thereby aiding gastroenterologists in treatment decisions. The company’s innovative platform features advanced capabilities such as multi-channel fluorescence imaging, image reading, image segmentation, and biomarker expression analysis. Cernostics aims to provide insights into disease pathophysiology, facilitate biomarker discovery and validation, and support clinical trials, ultimately enhancing patient outcomes and reducing healthcare costs. The company also collaborates strategically with Deciphex Limited to further advance its technological initiatives.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Celsense is a privately held biotechnology company based in Pittsburgh, Pennsylvania, founded in 2005. It specializes in developing novel magnetic resonance imaging (MRI) agents designed to non-invasively visualize and measure biological processes at the cellular level in humans and other living organisms. Celsense's products include Cell Sense, Gene Sense, and V-sense, which are used to image administration, migration, and persistence of transplanted cells, as well as to monitor inflammation and immune system response. These agents have applications in regenerative medicine, immunotherapy, and cancer treatment, enabling scientists and clinicians to track the location and quantity of transplanted cells. The company collaborates with leading pharmaceutical and biotechnology organizations to develop products suitable for human use.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, focused on developing and commercializing diagnostic blood tests that enhance personalized medicine. The company offers a range of products aimed at optimizing drug therapy in psychiatry and oncology. Its MyCare product line includes tests such as MyCare Psychiatry, which helps determine appropriate antipsychotic dosages; MyCare Oncology, which focuses on chemotherapy exposure optimization; and MyCare Neurology for assessing neurological drug effects. Key tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are designed to tailor chemotherapy treatments for various cancers. Saladax Biomedical markets its diagnostic solutions to healthcare providers worldwide through both distributors and direct sales, striving to empower physicians to deliver personalized care by ensuring optimal drug dosing. The company has been providing innovative diagnostic solutions for over 15 years.

Cellumen is a pioneering company in cellular systems biology (CSB) solutions, specializing in cell-based drug discovery, early safety assessment, and discovery toxicology. The company focuses on providing accurate predictions of drug efficacy and safety, which helps reduce failure rates and lower development costs for biopharmaceutical researchers. By addressing the complexities of disease and safety, Cellumen's CSB solutions enhance the drug development process. The company collaborates with leading global organizations, including the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH, and major pharmaceutical companies, to advance the field of drug research and ensure the creation of effective and safe patient-targeted therapies.

PeriOptimum provides workflow management solutions and consulting services for the healthcare industry. It offers real-time technology and process management solutions that allow hospitals to improve workflow in the operating room environment and also enables doctors, nurses, and managers to access patient location and clinical information. The company’s solution portfolio includes RealView, a real time workflow management system that allows users to see patient status in real-time and in multiple views; PeriOperative Improvement Evaluation, a process evaluation solution for on-site analysis and off-site data extraction and analysis; Surgical Analytics Services, a service to isolate, analyze, benchmark, and improve indicators; and Surgical Capacity Improvement Program, a process improvement program for the perioperative process. It also provides PeriOp Education Services, a program that enables hospitals to train their new recruits on critical topics and orient them on the hospital's perioperative department; PathFinder, an RFID-based tracking, workflow management, and communications system; and data analytics and workflow reengineering services.

ThermalTherapeutic Systems was founded in June, 2006 by a team of highly respected experts in the field of hyperthermic perfusion technology, medical device manufacturing, molecular diagnostics and technology commercialization.

Medrobotics Corporation, founded in 2005 and based in Raynham, Massachusetts, specializes in the development and commercialization of robotic surgical products. The company's flagship product is the Flex Robotic System, a robot-assisted platform designed to provide surgeons with single-site access and visualization of hard-to-reach anatomical locations. This system features a steerable and shapeable robotic scope, allowing surgeons to navigate complex anatomy through a small entry point. Medrobotics also offers a range of instruments compatible with the Flex system, including retractors and various surgical tools. The company's products are marketed in Europe.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Caliber Infosolutions, Inc. is a Pittsburgh-based company specializing in web-based software applications tailored for regulated industries, particularly in quality management for the pharmaceutical and biotechnology sectors. The company's flagship product, CaliberLIMS, automates batch, lot, and sample management, ensuring compliance with manufacturing specifications. Additionally, Caliber Stability facilitates the pre-registration of stability test protocols and provides statistical analyses of test results, while Caliber Pet-LIMS offers customizable laboratory information management solutions, including various reporting tools. Caliber also features Caliber CLAPS, a controlled label printing system designed for regulated environments. Alongside its software offerings, the company provides validation, implementation, training, and customer support services. Established in 2008, Caliber Infosolutions has formed strategic partnerships with industry leaders, enhancing its capabilities and reach within the biotech, pharmaceutical, oil, and petrochemical industries.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, focused on developing and commercializing diagnostic blood tests that enhance personalized medicine. The company offers a range of products aimed at optimizing drug therapy in psychiatry and oncology. Its MyCare product line includes tests such as MyCare Psychiatry, which helps determine appropriate antipsychotic dosages; MyCare Oncology, which focuses on chemotherapy exposure optimization; and MyCare Neurology for assessing neurological drug effects. Key tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are designed to tailor chemotherapy treatments for various cancers. Saladax Biomedical markets its diagnostic solutions to healthcare providers worldwide through both distributors and direct sales, striving to empower physicians to deliver personalized care by ensuring optimal drug dosing. The company has been providing innovative diagnostic solutions for over 15 years.

Lipella Pharmaceuticals is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on developing innovative treatments for urinary bladder conditions. Founded in 2005, the company specializes in intravesical therapy, delivering local treatments directly to the urinary bladder through urethral catheterization. Its product pipeline includes LP-10 (liposomal tacrolimus) for hemorrhagic cystitis and other candidates like LP-310 and LP-410 targeting conditions such as oral lichen planus and oral graft. Lipella Pharmaceuticals aims to improve supportive care for cancer survivors and address chronic bladder conditions, including interstitial cystitis and overactive bladder, which currently lack effective treatments.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

ParentPlus was formed to alleviate male-factor subfertility by bringing innovative biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized ― perhaps in part because it is not typically discussed in the popular press.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Crystalplex Corporation, founded in 2001 and based in Pittsburgh, Pennsylvania, specializes in the development of advanced nanocrystals, specifically its proprietary Sapphire quantum dots. These high-stability quantum dots are designed for a range of applications, including photoluminescent, electroluminescent, and photovoltaic technologies. Crystalplex's innovative products cater to various markets, including biomedical research, molecular diagnostics, and pathology, offering improved test results from smaller samples and reduced time and costs. Additionally, their quantum dots meet environmentally responsible standards while providing superior performance for high-end consumer electronics, such as LCD TVs and architectural lighting. The company focuses on cost-effective manufacturing techniques, ensuring robust and flexible crystal designs that enhance brightness and color quality in electronic displays.

Applied Isotope Technologies, Inc. is a Pittsburgh-based company established in 2003 that specializes in providing advanced measurement solutions for environmental and biological analyses. The company develops and manufactures a range of products, including isotopic spikes, analytical standards, reagent kits, and software designed for elemental, speciated, and molecular measurements. Its patented technologies, such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), are utilized across various sectors, including industrial, medical, and academic fields, to ensure accurate and reliable analytical results. Applied Isotope Technologies also offers training, QA certification, and technical support to assist laboratories in implementing its measurement methodologies. The company’s applications extend to environmental toxin detection, food safety analysis, and biomarker measurement, highlighting its commitment to delivering precise solutions in analytical chemistry.

Separation Design Group, LLC is a research and product development firm based in Waynesburg, Pennsylvania, founded in 2003. The company specializes in the design and manufacture of miniature oxygen generators for a variety of applications, including wound care, respiratory disease management, organ transplantation, and veterinary care. Its innovative technologies include portable medical oxygen concentrators, oxygen therapy devices, and oxygen generation modules for ozone generation. Additionally, the company develops solutions for personal and sports oxygen use and hybrid fuel electric aircraft engines. With research facilities located in Pittsburgh, Pennsylvania, and Morgantown, West Virginia, Separation Design Group focuses on creating energy-efficient equipment that operates at faster cycle times, thereby enhancing performance across industrial, medical, and commercial sectors.

InteloMed, Inc. is a medical device manufacturer focused on enhancing cardiovascular monitoring to improve patient outcomes. Founded in 2005 and based in Warrendale, Pennsylvania, the company specializes in noninvasive, real-time monitoring solutions through its CVInsight Patient Monitoring & Informatics System. This system captures and processes a patient's pulse waveform using proprietary algorithms, providing actionable health information for at-risk patients across various settings, including hospitals, outpatient facilities, and home care. InteloMed's technology is particularly beneficial in the management of conditions such as hemodialysis, heart failure, and perioperative care, offering clinicians vital insights into patients' cardiovascular stability for effective diagnosis and treatment planning.

ChemDAQ, Inc. is a manufacturer of gas detection systems designed to protect personnel from exposure to toxic sterilant gases. Founded in 1996 and based in Pittsburgh, Pennsylvania, the company provides solutions such as the ChemDAQ sterilant gas monitoring system and the ChemDAQ data acquisition module. These systems enable continuous monitoring, data recording, and documentation of sterilant gas levels, ensuring safety in various environments. ChemDAQ primarily serves hospitals and organizations within the healthcare, medical device manufacturing, and food and beverage industries, helping them maintain a safe and productive work environment.

Celsense is a privately held biotechnology company based in Pittsburgh, Pennsylvania, founded in 2005. It specializes in developing novel magnetic resonance imaging (MRI) agents designed to non-invasively visualize and measure biological processes at the cellular level in humans and other living organisms. Celsense's products include Cell Sense, Gene Sense, and V-sense, which are used to image administration, migration, and persistence of transplanted cells, as well as to monitor inflammation and immune system response. These agents have applications in regenerative medicine, immunotherapy, and cancer treatment, enabling scientists and clinicians to track the location and quantity of transplanted cells. The company collaborates with leading pharmaceutical and biotechnology organizations to develop products suitable for human use.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

STARR Life Sciences Corp. specializes in developing and manufacturing equipment for small animal research, catering to the needs of life science laboratories globally. Founded in 2004 and based in Oakmont, Pennsylvania, the company offers a diverse range of products designed specifically for mice, rats, and other small animals. Key offerings include the MouseOX Plus, a pulse oximeter that measures vital signs such as heart rate and arterial oxygen saturation, and the E-Mitter Telemetry System, which allows continuous monitoring of temperature, motor activity, and heart rate. Additionally, STARR Life Sciences provides various sensors, software modules, and activity monitoring systems that enable researchers and veterinarians to track the health and behavior of their subjects without causing disruption. Their products are utilized by universities, pharmaceutical companies, and contract research organizations, reflecting the company’s commitment to advancing medical research through innovative solutions.

Lipella Pharmaceuticals is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, focused on developing innovative treatments for urinary bladder conditions. Founded in 2005, the company specializes in intravesical therapy, delivering local treatments directly to the urinary bladder through urethral catheterization. Its product pipeline includes LP-10 (liposomal tacrolimus) for hemorrhagic cystitis and other candidates like LP-310 and LP-410 targeting conditions such as oral lichen planus and oral graft. Lipella Pharmaceuticals aims to improve supportive care for cancer survivors and address chronic bladder conditions, including interstitial cystitis and overactive bladder, which currently lack effective treatments.

Applied Computational Technologies is a software development company specializing in applications for the life sciences sector, particularly in radiation treatment planning for cancer therapy. The company has developed innovative software products, including ProACTive, a dose calculation engine designed to facilitate treatment planning for adaptive radiotherapy. With a significant number of cancer diagnoses in the United States, where a large percentage of patients undergo radiation therapy, Applied Computational Technologies aims to enhance the precision and effectiveness of cancer treatments through its advanced technological solutions.

RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, specializing in oncology support services. Founded in 2004, the company operates a diagnostic platform known as PathFinderTG, which focuses on the early and definitive diagnosis of cancer. This platform utilizes advanced techniques to analyze genetic mutations, extracting objective and quantitative genetic information from small tissue biopsies, cytology samples, and fluid specimens. By providing these insights, RedPath aids pathologists, clinicians, and patients in resolving complex diagnostic challenges, particularly in cases where cancer treatments do not produce expected results.

Immunetrics, Inc. is a biosimulation company based in Pittsburgh, Pennsylvania, established in 2003. It specializes in developing biological models and innovative tools for mechanistic modeling, particularly in the context of drug discovery and development. The company offers a software platform called Aegis, designed for model developers, along with disease-specific models and component model libraries. Its modeling software facilitates the creation of models, virtual populations, and experiments, enabling in-depth analysis of human diseases and syndromes. Additionally, Immunetrics provides consulting services in mechanistic and statistical modeling, as well as data analysis, aimed at predicting clinical outcomes of therapeutic interventions for various inflammatory and autoimmune diseases at both individual and trial population levels.

Proteopure offers protein isolation solutions for proteomic results. The company provides a universal method for isolating proteins. Its sample preparation kit uses a protein capture technology, and can specifically separate out proteins from various contaminants, including salts, nucleic acids, and detergents. Proteopure is headquartered in Pittsburgh, Pennsylvania.

Diamyd Medical AB is a Swedish biotechnology company focused on developing therapies for autoimmune diabetes. The company is advancing its lead product, Diamyd, an antigen-specific immunomodulating vaccine designed for the treatment of type 1 diabetes and latent autoimmune diabetes, which is currently in Phase IIb clinical development. Additionally, Diamyd Medical is working on Remygen, an oral regenerative and immunomodulatory drug candidate aimed at treating autoimmune and type 2 diabetes, now in Phase I/II clinical trials. The company also leverages its GABA technology, which is integral to its proprietary drug product development. Founded in 1984 and located in Stockholm, Sweden, Diamyd Medical was previously known as Diamyd Therapeutics AB until its name change in April 2013.

Applied Isotope Technologies, Inc. is a Pittsburgh-based company established in 2003 that specializes in providing advanced measurement solutions for environmental and biological analyses. The company develops and manufactures a range of products, including isotopic spikes, analytical standards, reagent kits, and software designed for elemental, speciated, and molecular measurements. Its patented technologies, such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), are utilized across various sectors, including industrial, medical, and academic fields, to ensure accurate and reliable analytical results. Applied Isotope Technologies also offers training, QA certification, and technical support to assist laboratories in implementing its measurement methodologies. The company’s applications extend to environmental toxin detection, food safety analysis, and biomarker measurement, highlighting its commitment to delivering precise solutions in analytical chemistry.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Blue Belt Technologies, Inc. specializes in developing and commercializing robotics-assisted technologies for orthopedic surgery and other medical specialties. The company is known for its Navio surgical system, which combines handheld intelligent instruments with a CT-free registration and patient-specific planning process, enhancing the precision of surgical procedures. Additionally, Blue Belt offers the STRIDE unicondylar knee system, designed to address early-stage osteoarthritis in the knee. Their software applications assist surgeons in creating tailored implant plans for unicondylar and patellofemoral knee replacements, ensuring proper localization of components and soft-tissue balance. Beyond its technological offerings, Blue Belt provides support services, marketing resources, maintenance programs, and onsite training for healthcare professionals. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in 2016.

MedSage Technologies specializes in providing software solutions and services tailored to healthcare providers within the burgeoning home medical equipment sector. Their offerings include comprehensive management systems for conditions such as obstructive sleep apnea and diabetes, along with services for rental equipment, respiratory medications, sleep lab outcomes, and enteral nutrition management.